- Hindi news
- Covaxin Proved Protection Against The New Corona Variants | Double Mutant, Eliminates Variants, Covaxin Also Effective On UK, Brazil And South African Variants
Fed up with Ads? Install Dainik NewsBust India app for news without ads
New yorkMoments before
- Copy link
The US Independent Journal Clinical Infectious Disease reported good news about Corona’s indigenous vaccine covaxin on Sunday. Their study claimed that covaxin provides considerable protection against the double mutant corona variant found in India. It also eliminates many other strains including variants found in Britain.
The study was based on an independent assessment of the study of Bharat Biotech. Earlier, the Indian Council of Medical Research (ICMR) also described Kovaxin as effective on almost all major variants.
Covaxin effective up to 78% in third phase clinical trials
Bharat Biotech, a Hyderabad-based company that manufactures the Corona vaccine, and the Indian Council of Medical Research (ICMR) recently released an interim clinical trial report for the third phase of covaxine. The report described covaxin manufactured in India as clinically 78% and up to 100% effective on patients severely affected by corona. The company, in its second analysis, did research on Corona’s 87 systems.
The company subsequently analyzed 127 symptoms for the third phase following the increased infection. In this, covaxin afficacy was found to be up to 78%. The company will release the final vaccine report in June. The third phase study included 25,800 people between the ages of 18–98, with 10% of those over 60 years.
What does it mean?
Bharat Biotech has made Kovacsin on a traditional platform. In this, inactivated virus is injected into the body, which does not grow in the body, but it prepares antibodies to fight. The good thing is that it targets the entire virus, so it is effective even if it changes. The best thing is that covaxin is the first such vaccine in the world, which has the power to fight all the variants.
Covaxin effective against all variants of Corona
Dr. Krishna Alla, chairman and managing director of Bharat Biotech, says that the vaccine has been used on 27,000 volunteers in all three phases of clinical trials. With the results of Phase-3 clinical trials, it has been proven that covaxin is effective against coronaviruses. This vaccine is also effective against other variants of coronavirus that are rapidly emerging.
Covaxin’s vestage also reduced
Covaxin or BBV152 is a Whole Viron inactivated SARS-CoV-2 vaccine. It is made from Vero Sales. It is stable at 2 to 8 ° C and is being transported in ready-to-use liquid formation. It is suitable for existing vaccine supply chain channels. BBV152 is also accompanied by a 28-day open cell policy, which reduces the vaccine waste by 10-30%.